Preoperative systemic treatment in BRCA-positive breast cancer patients

• Verfasst von: Schott, Sarah [VerfasserIn]
• Verfasst von: Sohn, Christof [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Verfasst von: Heil, Jörg [VerfasserIn]
• Titel: Preoperative systemic treatment in BRCA-positive breast cancer patients
• Titelzusatz: case report and review of the literature
• Verf.angabe: Sarah Schott, Christof Sohn, Andreas Schneeweiss, Joerg Heil (University Hospital Heidelberg, Women’s Hospital, National Center of Tumor Disease, Heidelberg, Germany)
• E-Jahr: 2011
• Jahr: [October 2011]
• Umfang: 4 S.
• Fussnoten: Gesehen am 26.10.2022
• Titel Quelle: Enthalten in: Breast care
• Ort Quelle: Basel : Karger, 2006
• Jahr Quelle: 2011
• Band/Heft Quelle: 6(2011), 5 vom: Okt., Seite 395-398
• ISSN Quelle: 1661-3805
• DOI: doi:10.1159/000333129
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1820016781

Abstract

Background: In vitro and in vivo analyses have shown differences in chemosensitivity between breast cancers associated with BRCA1/2 mutations compared to sporadic variants. In the preoperative setting, the tumor response can be directly measured. Therefore, preoperative systemic treatment (PST) offers the opportunity to assess the chemosensitivity in vivo. However, there have been neither clear guidelines for mutation carriers in terms of choice of chemotherapy regimen nor recommendations how to proceed in case of an inadequate response to PST. Case Report: Herein, we present the history of a 39-year-old woman with bilateral breast cancer who was tested positive for germ-line BRCA1 mutation while under PST. We performed a comprehensive literature review covering the MEDLINE database from 1992 to 2010 on published data regarding PST options for BRCA mutation carriers. Conclusions: If results of genetic testing are obtained during PST, individual therapy adaptations can be discussed with respect to mainly retrospective data of response to specific drugs. However, larger studies with longer follow-up are eagerly needed to draw firm conclusions before any specific treatment recommendations can be given for BRCA mutation carriers. PST is an ideal setting to evaluate such treatment options and to describe predictive markers that can help define subgroups that benefit most.